Mizuho Securities Downgrades DepoMed Inc (DEPO) to Neutral
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Mizuho Securities downgraded DepoMed Inc (NASDAQ: DEPO) from Outperform to Neutral with a price target of $27.00 following recent outperformance.
Analyst Irina Koffler commented, "We downgrade to Neutral and reiterate our blended $27 PT as we think that valuation has gotten too rich for new buyers after a favorable Nucynta litigation outcome. We continue to view a takeout at $29 as the most likely outcome for DEPO but believe the upside is relatively limited from here."
Shares of DepoMed Inc closed at $25.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108
- Imperial Capital Raises Price Target on Spirit Airlines (SAVE); Cuts 4Q Estimates
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!